Top

Published in:

Open Access 01-12-2003 | Editorial

First anniversary of Molecular Cancer: achievements and future goals

Authors: Arun B Deora, Karsta Luettich, Christian Schmidt, Guido M Sclabas

Published in: Molecular Cancer | Issue 1/2003

Abstract

Molecular Cancer has been launched for one year now. Here, we describe achievements of the past year and future goals of the journal.

Available only for authorised users

Wylie C: A time of change. Development. 2002, 129: 5552-10.1242/dev.00208.CrossRef

Atlas R, Campbell P, Cozzarelli NR, Curfman G, Enquist L, Fink G, Flanagin A, Fletcher J, George E, Hammes G, Heyman D, Inglesby T, Kaplan S, Kennedy D, Krug J, Levinson RE, Marcus E, Metzger H, Morse SS, O'Brien A, Onderdonk A, Poste G, Renault B, Rich R, Rosengard A, Salzburg S, Scanlan M, Shenk T, Tabor H, Varmus H, Wimmer E, Yamamoto K: Uncensored exchange of scientific results. Proc Natl Acad Sci USA. 2003, 100: 1464- 10.1073/pnas.0630491100CrossRefPubMed

Cozzarelli NR: Unfettered access to published results. Proc Natl Acad Sci USA. 2001, 98: 8159- 10.1073/pnas.171309098PubMedCentralCrossRefPubMed

Cozzarelli NR: For free access, follow the brick red buttons. Science. 2001, 292: 51-52. 10.1126/science.292.5514.51cCrossRefPubMed

Luttich K, Schmidt C, Sclabas G M.: Frequently asked questions about Molecular Cancer. Mol. Cancer. 2003, 2: 16- 10.1186/1476-4598-2-16PubMedCentralCrossRef

Till JE: Success factors for open access. J. Med. Internet Res. 2003, 5: E1-PubMedCentralCrossRefPubMed

Newmark P: Peer review and the rewards of open access. Nature. 2003, 422: 661- 10.1038/422661bCrossRefPubMed

Schmidt C: Bench and Bedside. Mol. Cancer. 2002, 1: 1- 10.1186/1476-4598-1-1PubMedCentralCrossRef

Gao X, Loggie BW, Nawaz Z: The roles of sex steroid receptor coregulators in cancer. Mol. Cancer. 2002, 1: 7- 10.1186/1476-4598-1-7PubMedCentralCrossRefPubMed

10.

Zhang P, Gao WY, Turner S, Ducatman BS: Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer. 2003, 2: 1- 10.1186/1476-4598-2-1PubMedCentralCrossRefPubMed

11.

Kunz M, Ibrahim SM: Molecular responses to hypoxia in tumor cells. Mol. Cancer. 2003, 2: 23- 10.1186/1476-4598-2-23PubMedCentralCrossRefPubMed

12.

Vasseur S, Malicet C, Calvo EL, Labrie C, Berthezene P, Dagorn JC, Iovanna JL: Gene expression profiling by DNA microarray analysis in mouse embryonic fibroblasts transformed by rasV12 mutated protein and the E1A oncogene. Mol Cancer. 2003, 2: 19- 10.1186/1476-4598-2-19PubMedCentralCrossRefPubMed

13.

Lynch C, Tycko B, Bestor T, Walsh C: Reactivation of a silenced H19 gene in human rhabdomyosarcoma by demethylation of DNA but not by histone hyperacetylation. Mol Cancer. 2002, 1: 2- 10.1186/1476-4598-1-2PubMedCentralCrossRefPubMed

14.

Delsite R, Kachhap S, Anbazhagan R, Gabrielson E, Singh KK: Nuclear genes involved in mitochondria-to-nucleus communication in breast cancer cells. Mol Cancer. 2002, 1: 6- 10.1186/1476-4598-1-6PubMedCentralCrossRefPubMed

15.

Carew JS, Huang P: Mitochondrial defects in cancer. Mol Cancer. 2002, 1: 9- 10.1186/1476-4598-1-9PubMedCentralCrossRefPubMed

16.

Narayan G, Arias-Pulido H, Koul S, Vargas H, Zhang FF, Villella J, Schneider A, Terry MB, Mansukhani M, Murty VV: Frequent Promoter Methylation of CDH1, DAPK, RARB, and HIC1 Genes in Carcinoma of Cervix Uteri: Its Relationship to Clinical Outcome. Mol Cancer. 2003, 2: 24- 10.1186/1476-4598-2-24PubMedCentralCrossRefPubMed

17.

Wary K, Thakker G, Humtsoe J, Yang J: Analysis of VEGF-responsive Genes Involved in the activation of endothelial cells. Mol Cancer. 2003, 2: 25- 10.1186/1476-4598-2-25PubMedCentralCrossRefPubMed

Title: First anniversary of Molecular Cancer: achievements and future goals
Authors: Arun B Deora
Karsta Luettich
Christian Schmidt
Guido M Sclabas
Publication date: 01-12-2003
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2003
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-2-26

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2003

Retraction Note: Association of Ataxia Telangiectasia Mutated (ATM) Gene Mutation/Deletion with Rhabdomyosarcoma – retraction

Expression of CAAT Enhancer Binding Protein Beta (C/EBP β) in Cervix and Endometrium

Apoptosis: Targets in Pancreatic Cancer

TGFβ1 activates c-Jun and Erk1 via αVβ6 integrin

Genetic alterations in pancreatic carcinoma

Invasion and metastasis in pancreatic cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer